+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Cost effectiveness in screening of class I HLA antibodies in Thai pregnant women



Cost effectiveness in screening of class I HLA antibodies in Thai pregnant women



Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl. 1): 165-166



Fifty-seven sera obtained from pregnant women who attended antenatal clinic were screened for class I HLA antibodies by standard microlymphocytotoxicity test. The age ranged from 20 to 40 years (mean +/- SD = 30.4 +/- 5). The lymphocytes obtained from 98 HLA-typed persons were used as the panel which would include all common HLA-A and HLA-B antigens and as many rare antigens as possible. Eight out of 57 sera (14%) had HLA antibodies which reacted as follows: 3 sera had nonspecific antibodies, 3 sera had multispecific antibodies (B60 + B48 + B7, B60 + B61 + B13 and B51 + B35 + B53), one serum had a monospecific antibody (A2) and one serum was unidentified. The identified antibodies showed strong reactivity (r > 0.8). These sera will be used as HLA typing sera and exchanged with other HLA laboratories. The screening test for class I HLA antibodies in pregnant women attending the antenatal clinic is useful and practical. Several HLA antisera can be obtained at low cost. The cost of self-screening antisera was US$90/ml while the cost of commercial HLA typing sera is approximately US$250/ml, a factor to be considered by a new HLA laboratory with limited budget.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045660619

Download citation: RISBibTeXText

PMID: 7886563


Related references

A cost utility analysis of the right method for screening hemoglobin E among Thai pregnant women. Archives of Gynecology and Obstetrics 274(2): 88-90, 2006

Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women. Gynecologic and Obstetric Investigation 62(2): 89-96, 2006

Cost-effectiveness of HIV screening for incarcerated pregnant women. Journal of Acquired Immune Deficiency Syndromes 38(2): 163-173, 2005

Cost-Effectiveness Analysis of Screening Syphilis Among Pregnant Women. Value in Health 17(7): A509-A510, 2014

Universal HIV screening of pregnant women in England: Cost effectiveness analysis. BMJ 318(7199): 1656-1660, June 19, 1999

Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 359(9321): 1919-1920, 2002

Cost-effectiveness analysis of HIV screening in pregnant women in hospitals in the Paris region. Journal de Gynecologie, Obstetrique et Biologie de la Reproduction 19(1): 36-42, 1990

Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women. Pathogens and Global Health 110(7-8): 292-302, 2017

Cost effectiveness of hiv screening of pregnant women in hospitals of the paris area france. European Journal of Obstetrics & Gynecology & Reproductive Biology 37(1): 25-34, 1990

Screening pregnant women for autoimmune thyroid disease: a cost-effectiveness analysis. European Journal of Endocrinology 158(6): 841-851, 2008

Cost-effectiveness analysis of universal screening for thyroid disease in pregnant women in Spain. Endocrinologia Y Nutricion 62(7): 322-330, 2017

Cost effectiveness of interferon-γ release assay for TB screening of HIV positive pregnant women in low TB incidence countries. Journal of Infection 68(1): 32-42, 2014

Cost-effectiveness of universal and risk-based screening for autoimmune thyroid disease in pregnant women. Journal of Clinical Endocrinology and Metabolism 97(5): 1536-1546, 2012

Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago. Pediatrics 105(4): E54, 2000